Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$2.44 USD
+0.27 (12.44%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $2.45 +0.01 (0.41%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.44 USD
+0.27 (12.44%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $2.45 +0.01 (0.41%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Zacks News
Surging Earnings Estimates Signal Upside for Ensign Group (ENSG) Stock
by Zacks Equity Research
Ensign Group (ENSG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Pacific Biosciences (PACB) Reports Break-Even Earnings in Q4
by Zacks Equity Research
Pacific Biosciences (PACB) expects softness in first-quarter consumable sales.
Pacific Biosciences of California (PACB) Reports Break-Even Earnings for Q4
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 100.00% and 9.79%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Pacific Biosciences Stock Now
by Zacks Equity Research
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.
Pacific Biosciences (PACB) Up 2.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Pacific Biosciences Stock
by Zacks Equity Research
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.
Options Traders Expect Huge Moves in Pacific Biosciences (PACB) Stock
by Zacks Equity Research
Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately.
Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) gains from solid segmental contributions in the third quarter.
Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -26.67% and -21.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Pacific Biosciences of California (PACB) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Pacific Biosciences For Now
by Zacks Equity Research
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, contraction in gross margin remains a woe.
Why Is Pacific Biosciences (PACB) Up 0.2% Since Last Earnings Report?
by Zacks Equity Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences (PACB) Beats on Q2 Earnings & Revenues
by Zacks Equity Research
Pacific Biosciences (PACB) Q2 results gain from higher revenues and strong segmental performance. Contraction in gross margin remains a woe.
Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 11.11% and 10.58%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Pacific Biosciences of California (PACB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health
46 and You: Genetic Testing = Giant Growth Market
by Kevin Cook
Advances in genomic diagnostic technology have made testing affordable for the 99.0% of the world still in line.
Pacific Biosciences (PACB) Down 7.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences (PACB) Incurs Loss in Q1, Revenues Fall
by Zacks Equity Research
Pacific Biosciences' (PACB) segments see softness in Q1; merger with Illumina on track.
Will Pacific Biosciences of California (PACB) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacific Biosciences (PACB) Up 3.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences (PACB) Incurs Q4 Loss, Revenues Fall Y/Y
by Zacks Equity Research
Pacific Biosciences' (PACB) dismal fourth-quarter 2018 results can be attributed to disappointing performance by the company's Product Revenue segment.
Pacific Biosciences of California (PACB) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -61.54% and -7.37%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.